ADRX vs DMRA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ADRX · Adarx Pharmaceuticals$12.79 ▼ 9.68%
DMRA · Damora Therapeutics$23.22 ▼ 4.44%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ADRX -33.9%
- DMRA +12.4%
Head to head
| Metric | ADRX | DMRA |
|---|---|---|
| Price | $12.79 | $23.22 |
| Change today | ▼ 9.68% | ▼ 4.44% |
| Market cap | $1.42B | $1.44B |
| Return, 3 months | – | -23.4% |
| Return, year to date | – | +0.9% |
| Return, 1 year | – | +38.5% |
| P/E (TTM) | – | 13.6 |
| P/B | 2.5 | 3.9 |
| P/E percentile vs own 5y | 85th | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +258.7% | – |
| Net profit growth (YoY) | -42.4% | -921.1% |
| Gross margin | – | – |
| Operating margin | -1,735.0% | – |
| Net margin | -1,434.1% | – |
| Return on equity | – | -156.6% |
| Analyst target vs. price | +173.7% | +101.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 35 | 54 |
| 30-day volatility | 78.8% | 61.9% |
| Max drawdown, 1 year | -38.0% | -46.9% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DMRA is the largest of the group by market value.
- DMRA has been the calmest stock over the last 30 days.